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Noninvasive positive pressure ventilation (NIPPV) has been shown to improve exercise toler-
ance and health-related quality of life in patients with advanced COPD. This study tested
the feasibility of nocturnal NIPPV as an additional tool in a hospital-based pulmonary rehabil-
itation program. This prospective observational trial included forty COPD patients in GOLD
stage IV. NIPPV was successfully introduced and accepted during sleep by all patients. All
patients received pressure support ventilation for 7.9  0.5 h per day with an inspiratory
support of 17.5 4.4 cmH2O, and an expiratory pressure of 4.5  0.9 cmH2O. The outcome
of pulmonary rehabilitation in patients receiving nocturnal NIPPV was compared with the
results of forty matched control patients who underwent the same program. Rehabilitation
with nocturnal NIPPV resulted in the 6-minute walk test and in the longest non-stop walk
distance in improvements of 82 and 89 m, respectively, while patients without nocturnal venti-
latory support improved by 50 and 51 m (p< 0.04 and p< 0.03 between groups, respectively).
Further significant improvements were found for FEV1, lung hyperinflation, and blood gases in
the NIPPV treated, but not in the control subjects. Health-related quality of life, assessed by
the SF-36 questionnaire, improved moderately or largely in patients receiving NIPPV in the
categories role-physical, vitality, social function, and mental health. Control subjects
improved moderately in vitality only. In conclusion, nocturnal NIPPV is feasible and enhances
the effects of pulmonary rehabilitation in advanced stage COPD.
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Exercise intolerance is one of the most disabling factors in
patients with advanced chronic obstructive pulmonary
disease (COPD). Dyspnoea and/or fatigue are the most
important symptoms, resulting from impaired pulmonary
gas exchange, ventilatory insufficiency, peripheral muscle
dysfunction, cardiac dysfunction, or any combination of the
above. Anxiety and poor motivation may further attenuate
exercise tolerance.1
Pulmonary rehabilitation (PR) is an important part of the
management of advanced COPD.2 Randomized controlled
trials have shown that 3e12 weeks PR can reduce respira-
tory symptoms, improve exercise tolerance, improve
quality of life, and suggest that PR reduces the number of
hospitalizations.3e5
Noninvasive positive pressure ventilation (NIPPV) has
been suggested as an additional technique to enhance
functional capacity6 and sleep quality7 in advanced COPD
patients. Significant improvements in 6-minute walk
distance (6MWD) could be achieved in previous rehabilita-
tion programs when exercise training was performed during
the application of NIPPV.8,9 However, performing mask
ventilation during exercise training is associated with
practical difficulties. Only selected patients are able to
comply with the requirements of exercising and noninvasive
ventilation. To circumvent these practical disadvantages,
and to take advantage of the potential impact of NIPPV on
sleep quality, NIPPV and training were timely separated.
Similar to two previous clinical trials,10,11 NIPPV was
provided during sleep.
The aim of this study was to evaluate the feasibility of
nocturnal NIPPV as an additional treatment option in
patients with severe COPD during hospital-based PR. In
addition, the impact of NIPPV on functional status, lung
function, and health-related quality of life (HRQL) was
assessed.
Patients and methods
Patients, setting, and design of the study
This trial was designed as a prospective observational
study. Successive COPD patients in GOLD stage IV,1
receiving optimized medical treatment and long-term
oxygen treatment12 were recruited at a large, specialized
rehabilitation hospital (Klinikum Berchtesgadener Land,
Schoenau, Germany) from January to December 2006.
Subjects were not considered for this study if they had
previous NIPPV treatment or CPAP for obstructive sleep
apnoea, severe orthopaedic or neurologic problems that
reduce mobility or cooperation with physical training,
poor controlled coexisting psychiatric or unstable cardiac
disease, and acute exacerbation of COPD at any time
during PR. Acute exacerbation was defined according to
Madison13 and Anthonisen14 characterized by increased
breathlessness in combination with worsening of cough
and sputum production, change in the colour of the
sputum, and rising levels of C-reactive Protein (CrP). All
patients gave informed consent prior to inclusion into the
study.The outcomes of functional assessments and HRQL were
compared with the results of a control group consisting of
the same number of matched COPD patients not receiving
NIPPV. Control subjects were recruited from a pool of 230
stable, nonexacerbated COPD patients who also received
optimized medical treatment and oxygen, and who
completed the same PR program (see below) since January
2005. Patients who would not have received NIPPV due to
one or more of the above-described exclusion criteria were
not included into the pool of possible control patients.
Matching criteria were sex, age (5%), body mass index
(BMI; 10%), baseline 6-minute walk distance (5%), and
baseline PCO2 (5%).
The study protocol in its final version was approved by
the institutional ethics committee. It is registered at Clin-
icalTrials.gov (ID NCT00710463).Interventions
Rehabilitation program: hospital-based PR was performed
according to a fixed protocol, which was uniformly applied
to all subjects (NIPPV group and controls) at five days of the
week. The program consisted of supervised sessions of
aerobic upper and lower extremity endurance training.
Lower extremity exercising was performed on a treadmill or
on a cycle ergometer. The sessions were performed over up
to 60 min, including warm-up and cool-down exercises. In
addition, patients received 30e45 min training intervals,
including individually tailored strength training, diaphrag-
matic breathing and controlled coughing exercises, along
with activating physiotherapy. Twice per week, all patients
participated in education programs about self-management
and nutrition, and underwent reviews of the proper use of
NIPPV, oxygen therapy and inhalers.
Noninvasive ventilation: NIPPV was performed with
a BiPAP Synchrony (Respironics Inc., Murrysville, PA,
United States) or a VPAP III ST-A (Resmed Ltd, Bella Vista
NSW, Australia) ventilator in pressure support ventilation
mode. The aim of ventilation was a reduction of resting
PCO2 during spontaneous breathing by at least 10%, or into
the normal range (35e45 mmHg). Measurements for
determination of the resting PCO2 were performed at
admission, and follow-up measurements were performed in
the morning after nocturnal NIPPV, 2 h after switching from
mask ventilation to spontaneous breathing.
In the first days of treatment, inspiratory and expiratory
pressures were carefully up-titrated to obtain the best
ventilatory support. However, a minimum inspiratory
pressure of 16 cmH2O and a minimum expiratory pressure of
4 cmH2O must have been reached at the third day of
treatment.15 Patients without hypercapnia were ventilated
with these minimum pressures. Patients were advised to
use the ventilator for at least 6 h every day, preferably
during sleep at night. Best fitting nasal or full face masks
(Ultra Mirage II series, Resmed, Bella Vista NSW, Australia)
were selected according to the patient’s tolerance. Oxygen
was inserted into the ventilatory circuit in a flow rate that
kept the oxygen saturation during NIPPV at or above 90%. In
case of difficulties in the adaptation process of NIPPV,
patients were studied with polysomnography (including
capnography) to optimize NIPPV during sleep.
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Feasibility of NIPPV was determined by daily assessment of
patients’ adherence to NIPPV, and by measurement of the
average daily usage of NIPPV. The usage was calculated by
reading the hour meter of the ventilator at baseline and at
the end of the study.
Lung function and blood gases: spirometry and body
plethysmography (MasterScreen Body, Jaeger GmbH,
Hoechberg, Germany) were performed following the
guidelines of the American Thoracic Society16,17 using
reference values of the European Respiratory Society.18
Blood gases were analyzed (Radiometer ABL800, Willich,
Germany) at rest from the hyperaemic earlobe.
Functional capacity: six-minute walk distance was
determined based on the guidelines of the American
Thoracic Society.19 After a phase of recovery, patients were
instructed to walk at their fastest pace and to cover the
longest possible distance over 6 min. Oxygen saturation was
continuously monitored, and supplemental oxygen was
supplied to keep oxygen saturation> 90%. The oxygen
cylinder or liquid oxygen container was carried by a sepa-
rate person. The test was performed on a 30-m corridor by
technicians with specific experience. Patients who became
symptomatic (e.g., severe dyspnoea or physically exhaus-
tion) were instructed to stop and to continue as soon as
possible. For the 6MWD, the minimal clinically important
difference before and after PR was not yet firmly estab-
lished. Depending on the source, it had been considered to
be 35 m20 or 54 m.21 The distance walked until the first stop
was defined as the longest non-stop walk distance.
Health-related quality of life (HRQL) was assessed with
the self-administrated generic questionnaire SF-36,22e24
which consists of 36 questions covering eight health
concepts: physical function, bodily pain, role-function
physical, general health perceptions, vitality, social func-
tion, role-function emotional, and mental health. In addi-
tion, there are two summary scores, one for physical
activity, and one for mental health. For all measures of the
health components, scores were transformed linearly to
scales of 0e100, with 0 indicating maximal impairment and
100 indicating the minimal impairment.Statistical analysis
Values are presented as mean SD. For all tools, the values
obtained at baseline and after PR were compared using
a paired t-test, unpaired t-test, the Wilcoxon matched pairs
test, or the ManneWhitney test, as appropriate. Correla-
tionswere calculated by using Pearson’s correlation test. For
all tests, p< 0.05 was considered significant. The statistics
were completed using a standard statistical package (SPSS-
software Version 13.0, SPSS Inc., Chicago, IL, USA).
Clinically meaningful changes for the largest non-stop
walk distance and the SF-36 scores have not been defined in
pulmonary patients. One independent method of assessing
the magnitude of change is the effect size (ES), which is
a standardized measure of change within a group. The
effect size is calculated by dividing the mean change from
the initial score to the follow-up score by the SD of the
initial score, as follows: (Mean Initial ScoreMean Follow-up Score)/SD of Initial Score.25 While the magnitude of the
effect size that is clinically relevant for specific health
parameters has yet to be established, Cohen26 and others 27,28
have suggested that an effect size of 0.20 is small, 0.50 is
moderate, and >0.80 is large. Thus, the greater the effect
size, the stronger is the evidence that a change represents
a minimal clinically meaningful difference.Results
During the one-year study period, 55 consecutive patients
in GOLD stage IV were screened. Forty-three patients met
all in- and exclusion criteria and were enrolled into this
study. Three subjects developed an acute exacerbation of
COPD and terminated the study prematurely. These
patients were not included into the final data analysis.
Forty patients fulfilled all requirements.
NIPPV could be successfully introduced and continued
over the whole period of PR in all 40 patients. Within three
days after initiation of NIPPV, all patients felt comfortable
with the selected mask and the ventilatory mode (pressure
support ventilation). The average inspiratory pressure was
17.5 4.4 cmH2O, and expiratory pressure was
4.5 0.9 cmH2O. The average use of NIPPV was 7.9 0.5 h
per day. All subjects exceeded the minimum ventilatory
pressure limit of 16/4 cmH2O and the minimum daily
ventilator usage time of 6 h. Sixteen subjects, in whom the
requested CO2 reduction was not reached by day 3, were
observed with polysomnography over one or two nights.
Nocturnal optimisation of NIPPV resulted in all subjects in
the CO2 target required by the protocol.
The functional capacities and the HRQL of the 40
prospectively studied patients were compared to 40 control
subjects, who were matched according to the criteria
described above. At baseline, no statistically significant
differences could be found for patients in either group for
gender distribution, age, BMI, 6MWD, blood gases, lung
function, and the largest non-stop walk distance (Table 1).
Pulmonary rehabilitation was performed over 29.5 6.5
and 29.3 5.9 days in patients undergoing PR plus
nocturnal NIPPV versus PR alone, respectively (pZ 0.54).
The 6MWD increased on average by 50 m in the control
group, compared to 82 m in the NIPPV group (p< 0.04,
Fig. 1). The largest non-stop walk distance increased by
51 m in the control group, while the NIPPV group increased
by 89 m (p< 0.03, Fig. 2). The effect size determination of
the improvements in both tests indicates large and
moderate improvements in PR patients with NIPPV,
compared to moderate and small improvements for PR
patients without NIPPV (Table 2). The minimal clinically
important difference in the 6MWD of 35 m20 was reached by
78% of the subjects in the NIPPV group, versus 58% in
control group subjects.
During PR, patients with NIPPV demonstrated significant
improvements in blood gases and in the measurement of the
quotient of Residual Volume and Total Lung Capacity (RV/
TLC), a surrogate of lung hyperinflation, while FEV1 and
FEV1% predicted improved without reaching statistical
significance. In contrast, spirometry, body plethysmography,
and blood gases did not change relevantly within control
subjects (Table 2). The improvements of functional capacity
Figure 1 Changes in the six-minute walk distance from
baseline to the end of a 29-day, hospital-based, intensive
pulmonary rehabilitation (PR) program. Patients who had been
started on nocturnal NIPPV at the beginning of the rehabilita-
tion program (right) revealed significantly better increases in
the distance walked in 6 min than patients undergoing the
same program without additional NIPPV treatment (left).
Table 1 Subject characteristics at baseline.
PR with NIPPV,
nZ 40
PR without NIPPV,
nZ 40
p-Value
Sex (m/f) Male/female 18/22 20/20 n.d.
Age [years] 57.9 9.1 56.8 8.0 0.53
BMI [kg/m2] 21.7 4.6 22.3 3.8 0.7
LTOT flow rate [l/min] 3.7 0.8 3.4 0.9 0.56
Post-bronchodilator FEV1 [l] 0.72 0.26 0.69 0.18 0.81
Post-bronchodilator FEV1 % of predicted 26.4 11.4 25.5 7.2 0.54
TLC % of predicted 131.4 25.6 139.2 12.5 0.41
RV/TLC % 75.2 8.7 76.7 6.5 0.75
pO2
a [mmHg] 53.4 7.6 56.2 7.4 0.19
PCO2
b [mmHg] 53.2 9.8 51.7 7.8 0.22
Patients with PCO2 45 mmHg n 7 9
Patients with PCO2> 45 mmHg
and 50 mmHg
n 7 5
Patients with PCO2> 50 mmHg n 26 26
6MWD [m] 243 91 245 88 0.97
Largest non-stop walk distance [m] 219 116 210 115 0.81
PR: pulmonary rehabilitation, NIPPV: noninvasive positive pressure ventilation, BMI: body mass index, LTOT: long-term oxygen treat-
ment, FEV1: forced expiratory volume in the first second, TLC: total lung capacity, RV: residual volume, 6MWD: 6-minute walk distance,
and n.d.: not done.
a Measured during rest while breathing room air.
b Measured during rest with the prescribed flow rate of oxygen.
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inflation (RV/TLC), or with FEV1 (data not shown).
Noninvasive ventilation was applied independently of
baseline PCO2. Subgroup analysis of all patients with
PCO2 50 mmHg revealed that NIPPV produced similar
treatment effects in patients above or below this threshold
(Table 3).
Quality of lifemeasurementswere performedwith the SF-
36 questionnaire in 35 patients in the NIPPV group and in 34
control group subjects. Patients with NIPPV treatment had
worse baseline scores for bodily pain, vitality, social func-
tion, role-functionemotional,mental health, and themental
component summary score, compared to the control group.
Patients with NIPPV revealed clinically relevant improve-
ments (moderate or large effect sizes) in 4 categories of the
SF-36 questionnaire and in one summary score, while control
subjects reported a relevant improvement in the category
‘vitality’ only (Fig. 3 and Table 4).
Discussion
The addition of nocturnal NIPPV treatment to a hospital-
based, intensive PR program is feasible and accepted by
patients with advanced COPD. Our study supports the
previously documented, beneficial effects of PR on func-
tional capacity and HRQL.3 In addition, the present findings
suggest that the effects of an intensive, three to five
weeks, inpatient rehabilitation program can be extended,
if patients receive nocturnal NIPPV, although the results of
our secondary outcome parameter 6MWD, longest non-stop
walk distance, and HRQL had been compared to a historical
control group.
The professional environment of a rehabilitation
hospital might have been an important reason for thesuccessful NIPPV implementation and adherence of
patients to this treatment. Careful uptitration of pressure
support might have been the reason for the achievement of
satisfactory ‘‘doses’’ of NIPPV, judged from average use of
NIPPV of 7.9 h per day and the pressure levels applied. With
the special setting, design and the close observation of
patients, this study avoided the shortcomings of a previous
study with similar treatment intention,29 which failed to
Figure 2 Changes in largest non-stop walk distance from
baseline to the end of a 29-day, hospital-based, intensive
pulmonary rehabilitation (PR) program. Patients who had been
started on nocturnal NIPPV at the beginning of the rehabilita-
tion program (right) revealed significantly better increases in
the largest non-stop walk distance than patients undergoing
the same program without additional NIPPV treatment (left).
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adjunct to an outpatient PR program.
The PR effects in patients without receiving NIPPV were
comparable to previous, controlled studies. Salman et al.5
analyzed six studies of COPD patients with similar baseline
FEV1 as in our cohort. These patients underwent 8 weeks to
12 months outpatient PR and developed increases in 6MWD
with an ES of 0.63. However, outpatient PR programs with
less than 3 months duration did not provide any relevant
benefit in severe COPD. A previous meta-analysis, published
by Lacasse et al. in 1996,4 analyzed 11 studies with similarTable 2 Outcome of pulmonary rehabilitation in COPD patients
PR with NIPPV, nZ 40
Baseline Post-PR 95%
CI of changes
within the
NIPPV group
p Effec
size
FEV1 [l] 0.72 0.79 0.04e0.13 0.25
FEV1% predicted 26.4 30.0 0.6e8.5 0.16
TLC% predicted 131.4 128.9 7.5 to 3.8 0.64
RV/TLC [%] 75.2 72.2 5.79 to 0.34 0.04
pO2 [mmHg] 53.4 58.2 0.1e3.9 0.04
PCO2 [mmHg] 53.8 46.7 5.6 to 9.4 <0.01
6MWD [m] 243 325 60.6e101.8 <0.01 0.89
Largest non-stop
walk distance
[m]
219 308 60.6e110.6 <0.01 0.74COPD patients. Most studies included were performed in an
outpatient setting, and 6 weeks to 6 months PR resulted in
an average increase of 6MWD of 55.7 m with an average
effect size of 0.6. The PR program in the current study was
shorter but more intense, included only patients in GOLD
stage IV, and its effects seem to equal previous outpatient
PR studies.
The combination of PR and nocturnal NIPPV produced
additional improvements in 6MWD, the largest non-stop
walking distance, another surrogate of endurance,30 FEV1,
and lung hyperinflation. Since the largest non-stop walk
distance was determined during the 6-minute walk test,
a test assessing the submaximal level of exercise capacity,
the ‘real’ largest non-stop walk distance might have been
underestimated in some patients who continuously walked
until the test was terminated after 6 min.
The current trial demonstrates comprehensively the
benefits of NIPPV as an adjunct to COPD rehabilitation,
regarding functional capacity and HRQL. This extends the
observations of two previous trials investigating nocturnal
NIPPV in outpatient rehabilitation of COPD patients. Garrod
et al.10 demonstrated in NIPPV treated subjects a statistical
significant increase of 100 m in shuttle walk tests per-
formed before and after 8 weeks PR training, compared to
28 m in the control group. Apart from an improvement in
fatigue, no significant differences were documented for
activities of daily living or anxiety between patients with or
without NIPPV treatment. With a similar study design,
Duiverman et al.11 found no significant changes in func-
tional capacity after three months outpatient rehabilita-
tion, but their assessment of HRQR revealed positive
effects on fatigue and cognition. These studies and our
results suggest an important influence of nocturnal NIPPV
on the effectiveness of PR. However, the ‘‘pure’’ effect of
NIPPV could not been determined in either study. In the
current study, we were not able to introduce a third limb
with patients receiving NIPPV without undergoing PR. NIPPV
without exercise training was previously evaluated in
a meta-analysis by Wijkstra et al.,31 which included two
small studies. The average increase in 6MWD was calcu-
lated on 27.5 m for patients using NIPPV over three months.with/without NIPPV. For abbreviations refer to Table 1.
Control group (PR without NIPPV), nZ 40 p-Value for
changes
between
groups
t Baseline Post-PR 95% CI of
changes within
the control
group
p Effect
size
0.69 0.67 0.04 to 0.01 0.55 <0.001
25.5 25.1 1.8 to 0.7 0.73 0.001
139.2 140.9 4.6 to 6.7 0.65 0.28
76.7 77.0 1.4 to 1.9 0.79 0.04
56.2 57.4 2.9 to 3.1 0.59 0.78
51.7 50.1 2.6 to 2.1 0.8 0.36
245 295 35.6 to 63.1 0.02 0.58 0.04
210 261 39.5 to 82.3 0.04 0.47 0.03
Table 3 Subgroup analysis of patients with a baseline PCO2 50 mmHg (nZ 28). For abbreviations refer to Table 1.
PR with NIPPV, nZ 14 Control group (PR without NIPPV), nZ 14 p-Value for
changes
between
groups
Baseline Post-PR 95%
CI of changes
within the
NIPPV group
p Effect
size
Baseline Post-PR 95% CI of
changes within
the control
group
p Effect
size
FEV1 [l] 0.82 0.91 0.05 to 0.16 0.52 0.82 0.74 0.07 to 0.05 0.35 0.01
FEV1% predicted 29.5 33.3 1.97 to 5.66 0.34 30.8 29.7 2.6 to 2.3 0.62 0.01
TLC % predicted 131.1 126.1 8.87 to 5.03 0.64 133.0 135.5 4.7 to 7.1 0.66 0.42
RV/TLC [%] 73.7 69.8 12.17 to 1.56 0.37 71.6 73.5 1.9 to 3.0 0.38 0.02
pO2 [mmHg] 56.3 60.8 1.63 to 8.51 0.27 60.9 60.6 3.6 to 3.0 0.9 0.17
PCO2 [mmHg] 44.0 40.1 9.34 to 1.25 0.37 44.2 41.1 4.43 to 2.81 0.58 0.23
6MWD [m] 244 340 59 to 132 0.01 0.97 251 306 36 to 72 0.1 0.59 0.03
Largest non-stop
walk distance
[m]
231 334 58 to 147 0.02 0.87 202 265 26 to 99 0.17 0.48 0.03
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magnitude as the differences in the current study found for
6MWD improvements in patients with or without NIPPV (82
versus 50 m).
Analysing physiologic causality of our observations was
beyond the scope of this study. However, positive pressure
ventilation provides direct mechanical support for the
overloaded ventilatory muscles in severe COPD.32 More
importantly, positive pressure ventilation may allow recu-
peration of breathing muscles and restoration of their
energy stores.33,34 In addition, improved bronchial airflow
limitation and pulmonary hyperinflation reduce of the work
of breathing.35 These mechanisms may contribute to the
better exercise tolerance in NIPPV treated subjects. The
impact of mechanical ventilation on the central control of
breathing36 may be an additional factor.
Previous investigators provided long-term NIPPV treat-
ment only for patients with some degree of hypercapnia, an0
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Figure 3 Health-related quality of life before and after pulmon
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nothing is known about the effects of nocturnal NIPPV on
exercise capacity in COPD patients with normal or only
slightly elevated daytime PCO2. The present study enrolled
patients and applied NIPPV, regardless of their baseline
PCO2 levels. Interestingly, subgroup analyses in patients
with a baseline PCO2 below 50 mmHg revealed similar
effects in the main outcome parameters (Table 3),
compared to the whole cohort. These observations favour
the concept of early implementation of positive pressure
ventilatory support in PR patients with severe COPD.
Further clinical and physiologic data are needed to support
these preliminary observations.
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culties during the implementation of nocturnal NIPPV, we
were not able to perform sleep studies in all patients to
determine the impact of nocturnal NIPPV on the sleep
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Table 4 Health-related quality of life before and after pulmonary rehabilitation with/without NIPPV. Subscores and summary
scores of the SF-36 questionnaire at baseline and after pulmonary rehabilitation (PR) with or without NIPPV. An effect size of
0.20 is small, 0.50 is moderate, and >0.80 is large.24
PR with NIPPV, nZ 35 PR without NIPPV, nZ 34
Baseline Post-PR Effect size Baseline Post-PR Effect size
Physical function 17.6 16.5 19.0 14.5 0.08 18.8 15.0 15.6 13.6 0.22
Bodily pain 38.3 14.5 45.1 12.6 0.47 53.0 11.2 52.5 10.8 0.05
Role-function physical 27.0 6.0 30.7 14.5 0.61 27.8 8.4 28.6 10.4 0.07
General health perceptions 34.2 4.3 33.1 9.6 0.26 32.6 12.9 36.5 10.6 0.31
Vitality 30.0 10.6 38.8 13.1 0.83 37.5 11.6 45.3 9.6 0.67
Social function 19.1 15.8 37.4 21.9 1.16 28.0 20.5 35.5 19.2 0.36
Role-function emotional 26.5 15.5 31.1 20.1 0.30 37.0 20.1 40.3 19.8 0.16
Mental health 33.9 17.0 43.6 18.2 0.57 44.4 13.0 49.1 12.1 0.36
Physical component
summary score
27.3 10.1 27.3 12.5 0.00 29.4 11.6 29.0 8.4 0.03
Mental component
summary score
28.8 19.1 42.7 23.6 0.73 42.1 18.0 50.1 15.1 0.44
NIPPV in pulmonary rehabilitation of COPD 1335satisfactory recuperation during sleep in NIPPV patients.
The categories vitality and social function improved with
large effect sizes, and mental health, role-function phys-
ical, and mental sum score improved with moderate ES. In
contrast, patients without NIPPV revealed moderate
improvements in vitality, but no relevant changes in any of
the other categories.
The length of PR (and study participation) varied
between three and five weeks with an average of 29.4 days.
The only reasons for these variations were differences in
cost reimbursement of the patients’ health care insurance,
a random variable not influenced by the investigators.
The lack of a prospective, randomized design for
assessment of functional capacity and HRQL, and the non-
blinding of subjects and investigators to the intervention
NIPPV are acknowledged limitations of the current study.
The protocol did not provide repeated measurements of
functional status or assessment of HRQL during PR, there-
fore we were not able to evaluate rehabilitation progress
over the time. Similar to many previous PR studies, we were
not able to perform follow-up observations of the partici-
pants after discharge from PR. Therefore, we had no
opportunity to estimate the impact of the rehabilitation
results on ability to work, limitations of physical exertion,
or social activities. The strengths of the presented study
are the large, homogeneous, and well-matched cohorts of
patients, who underwent a standardized, hospital-based PR
program. The rationale for the current study was a proof of
concept, and these data may serve as the basis for
prospective, randomized controlled trials with large study
populations and observations beyond the period of PR.
In conclusion, NIPPV is a feasible and beneficial tool in
hospital-based PR. Patients with severe COPD benefit
from a structured PR program, and improvements in
functional capacity and health-related quality of life can
be amplified, if PR is combined with nocturnal noninva-
sive positive pressure ventilation. Comparable treatment
effects had been found for patients with either normo-
capnia or only mild hypercapnia, and severe hypercapnia
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